Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples